pr-inside.com
Print

Change in the number of votes relating to Biotie Therapies Corp.'s shares



2013-01-03 10:16:47 -


Biotie Therapies Corp.          Stock Exchange Release    3 January 2013 at
11:15 a.m.

Change in the number of votes relating to Biotie Therapies Corp.'s shares

The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the
"Company"),
Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie
Therapies Holding AG) has conveyed Biotie shares against consideration pursuant
to the option programs as follows:

December 2012 Total (5/2011- Options % of the total
12/2012) outstanding amount of
shares

7,739 6,300,378 8,256,813 1.8




The conveyance of Biotie shares relates to the option plan of Synosia
Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia")
acquired by Biotie in February 2011. According to such Synosia share option
plan, options have been granted to employees, former directors and consultants.
In connection with the completion of the acquisition of Synosia, the option plan
was amended so that instead of shares in Synosia an aggregate maximum of
14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued
these 14,912,155 shares to its current subsidiary Synosia in connection with the
acquisition to be further conveyed to the option holders when they potentially
exercise their option rights in accordance with the terms and conditions of the
option program.

The conveyed shares previously held by the Company's subsidiary have not carried
any voting rights. The parent company Biotie does not own any treasury shares.
The conveyance does not affect the number of registered shares.

After the conveyances the changes are as follows:

The increase of vote of A total amount of The number of the The total number
the Company voting rights: Company's share held of registered
December 2012 by the Group shares
December 2012

7,739   444,098,961 8,611,777 452,710,738




Turku, 3 January 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Biotie Therapies Oyj via Thomson Reuters ONE
[HUG#1667984]


Press Information:




Contact Person:


Phone:
email: e-mail




Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.